<code id='B87691D7DC'></code><style id='B87691D7DC'></style>
    • <acronym id='B87691D7DC'></acronym>
      <center id='B87691D7DC'><center id='B87691D7DC'><tfoot id='B87691D7DC'></tfoot></center><abbr id='B87691D7DC'><dir id='B87691D7DC'><tfoot id='B87691D7DC'></tfoot><noframes id='B87691D7DC'>

    • <optgroup id='B87691D7DC'><strike id='B87691D7DC'><sup id='B87691D7DC'></sup></strike><code id='B87691D7DC'></code></optgroup>
        1. <b id='B87691D7DC'><label id='B87691D7DC'><select id='B87691D7DC'><dt id='B87691D7DC'><span id='B87691D7DC'></span></dt></select></label></b><u id='B87691D7DC'></u>
          <i id='B87691D7DC'><strike id='B87691D7DC'><tt id='B87691D7DC'><pre id='B87691D7DC'></pre></tt></strike></i>

          hotspot

          hotspot

          author:Wikipedia    Page View:1231
          Eli Lilly headquarters in Indianapolis – pharmaceutical coverage from STAT
          Darron Cummings/AP

          The Food and Drug Administration on Thursday approved an Eli Lilly drug that takes a new approach to treating ulcerative colitis, a chronic inflammatory disease that can cause intense gastrointestinal pain and distress.

          The therapy, dubbed Omvoh, is an antibody that blocks IL-23p19, an immune signaling molecule that plays a key role in sustaining the disease. It’s the first treatment to target this particular pathway in ulcerative colitis. The drug’s approval comes after two late-stage trials found that patients taking Omvoh showed a significant improvement in symptoms after both three months and a year compared with those given a placebo, and that the therapy had minimal side effects.

          advertisement

          Omvoh’s list price will be $9,593 per month for intravenous delivery and $10,360 per dose injected beneath the skin. A company spokesperson told STAT that patients who have the drug covered by commercial insurance may pay as little as $5 per month for up to 30 months.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          focus

          After affirmative action ruling, medical educators look to 'holistic review'
          After affirmative action ruling, medical educators look to 'holistic review'

          AnnaMoneymaker/GettyImagesAfterhavingadaytoreadthroughtheSupremeCourt’sdecisiononaffirmativeaction,s

          read more
          Biden has enormous polling lead in Democratic primary, despite challenge from RFK Jr.
          Biden has enormous polling lead in Democratic primary, despite challenge from RFK Jr.

          2:42PresidentJoeBidenspeaksintheEastRoomoftheWhiteHouseinWashington,July25,2023.SusanWalsh/APPreside

          read more
          The high cost of giving birth even with insurance
          The high cost of giving birth even with insurance

          AdobeTheburdenofhighhealthcarecostsandmedicaldebtintheU.S.isnosecret.Medicaldebtaffectsoneinfiveadul

          read more

          House GOP plan to stem drug shortages differs from Democrats’

          Rep.CathyMcMorrisRodgers(R-Wash.),chairoftheHouseEnergyandCommerceCommittee.AnnaMoneymaker/GettyImag